Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | TRHR | P34981 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27905689 | 1.00 | OPRK1 (0.44) | OPRK1TRHRHDAC3HDAC11HDAC6 | |
| SCHEMBL159687 | 1.00 | OPRK1 (0.44) | OPRK1TRHRHDAC3HDAC11HDAC6 | |
| SCHEMBL31061201 | 0.91 | OPRK1 (0.45) | OPRK1TRHRHDAC3HDAC11HDAC6 | |
| SCHEMBL22319323 | 0.89 | FOLH1 (0.46) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL22319322 | 0.89 | FOLH1 (0.46) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL11173161 | 0.89 | FOLH1 (0.46) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL11246319 | 0.88 | OPRK1 (0.49) | OPRK1HDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL31199140 | 0.88 | OPRK1 (0.41) | OPRK1TRHRHDAC3HDAC11HDAC6 | |
| SCHEMBL29713552 | 0.87 | OPRK1 (0.46) | OPRK1TRHRHDAC3HDAC11HDAC6 | |
| SCHEMBL29416863 | 0.87 | OPRK1 (0.46) | OPRK1TRHRHDAC3HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224855-A1 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | FRIESLANDCAMPINA NEDERLAND HOLDING B.V. (NL) | 2013-08-29 | — | — | US | claimed |
| CN-103097516-A | Culture medium for eukaryotic cells | FRIESLAND BRANDS BV | 2013-05-08 | — | — | CN | claimed |
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | claimed |
| EP-3967217-B1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | GLOBAL GENOMICS GROUP LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20240019417-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-01-18 | — | — | US | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | L'OREAL (FR) | 2022-08-02 | — | — | US | disclosed |
| WO-2013133714-A1 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | FRIESLAND BRANDS B.V. (NL) | 2013-09-12 | — | — | WO | disclosed |
| US-20130224855-A1 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | FRIESLANDCAMPINA NEDERLAND HOLDING B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| EP-2611904-A2 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | Friesland Brands B.V. (NL) | 2013-07-10 | — | — | EP | disclosed |
| US-20130115649-A1 | Methods and Reagents for Metabolomics and Histology in a Biological Sample and a Kit for the Same | METABOLON, INC. | 2013-05-09 | — | — | US | disclosed |
| CN-103097516-A | Culture medium for eukaryotic cells | FRIESLAND BRANDS BV | 2013-05-08 | — | — | CN | disclosed |
| US-20120192888-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L 'Oréal S.A., (FR) | 2012-08-02 | — | — | US | disclosed |
| WO-2012030217-A2 | CULTURE MEDIUM FOR EUKARYOTIC CELLS | FRIESLAND BRANDS B.V. (NL) | 2012-03-08 | — | — | WO | disclosed |
| US-20100163070-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBRES USING HEATING MEANS AND AN AMIDE | L'OREAL S.A. (FR) | 2010-07-01 | — | — | US | disclosed |
| US-20100028280-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L'OREAL S.A. (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120192888-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | KRT18, KRTCAP2, TUBB4A | OPRK1 4519/4885TRHR 4690/4885HDAC3 2585/4885 |
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | KRT18, KRTCAP2, TUBB4A | OPRK1 4519/4885TRHR 4690/4885HDAC3 2585/4885 |
| US-20100028280-A1 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | KRT18, KRTCAP2, TUBB4A | OPRK1 4519/4885TRHR 4690/4885HDAC3 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.